PRINCETON, NJ--(Marketwired - January 14, 2016) - Adgero Biopharmaceuticals, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company, leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious oncology indications, announced today that it will present at NobleCon12, the Noble Financial Capital Markets' 12th Annual Investor Conference, on Monday, January 18, 2016 at 9:00 a.m. ET in Sandpiper Bay, FL.
Frank G. Pilkiewicz, Ph.D., Chief Executive Officer, will present an overview of the Company's lead product candidate REM-001 Therapy, which has demonstrated promising safety and efficacy results in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC"), the majority of whom have failed radiation therapy.
Dr. Pilkiewicz will also review the strategy for clinical and regulatory advancement of REM-001 Therapy, including anticipated filings for Orphan Drug and Breakthrough Therapy designations in 2016. Additionally, he will discuss Adgero's growth strategy focused on potential pipeline expansion into additional high-value cutaneous cancer indications.
A live webcast of the presentation will be available on the Company's website at www.AdgeroBiopharm.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.
About Noble Financial Capital Markets
Noble Financial Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences. For more information: www.noblefcm.com.
About Adgero
Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous (skin surface) metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
For more information, please visit www.AdgeroBiopharm.com.
Frank G. Pilkiewicz, Ph.D., Chief Executive Officer, will present an overview of the Company's lead product candidate REM-001 Therapy, which has demonstrated promising safety and efficacy results in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC"), the majority of whom have failed radiation therapy.
Dr. Pilkiewicz will also review the strategy for clinical and regulatory advancement of REM-001 Therapy, including anticipated filings for Orphan Drug and Breakthrough Therapy designations in 2016. Additionally, he will discuss Adgero's growth strategy focused on potential pipeline expansion into additional high-value cutaneous cancer indications.
A live webcast of the presentation will be available on the Company's website at www.AdgeroBiopharm.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.
About Noble Financial Capital Markets
Noble Financial Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences. For more information: www.noblefcm.com.
About Adgero
Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous (skin surface) metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
For more information, please visit www.AdgeroBiopharm.com.
